Results 1 to 10 of about 2,399 (178)
LDL-Apheresis: Technical and Clinical Aspects [PDF]
The Scientific World Journal, 2012 The prognosis of patients suffering from severe hyperlipidemia, sometimes combined with elevated lipoprotein (a) levels, and coronary heart disease refractory to diet and lipid-lowering drugs is poor. For such patients, regular treatment with low-density
Rolf Bambauer +4 more
doaj +5 more sources
LDL apheresis as an alternate method for plasma LPS purification in healthy volunteers and dyslipidemic and septic patients [PDF]
Journal of Lipid Research, 2020 Lipopolysaccharide (LPS) is a key player for innate immunity activation. It is therefore a prime target for sepsis treatment, as antibiotics are not sufficient to improve outcome during septic shock.
Auguste Dargent +12 more
doaj +2 more sources
Management of Pregnancy in a Patient with Familial Hypercholesterolemia and Previous Myocardial Infarction—Treatment with LDL Apheresis: A Case Report [PDF]
ReportsFamilial hypercholesterolemia, a genetic disorder marked by elevated low-density lipoprotein cholesterol (LDL-C), poses significant risks for premature atherosclerosis and cardiovascular diseases, particularly during pregnancy. One of the safe methods of
Milos Milincic +6 more
doaj +2 more sources
Journal of Lipid Research, 2000 Epidemiologic studies and in vitro experiments indicate that low density lipoprotein (LDL) subtypes differ concerning their atherogenic potential. Small, dense LDL are more atherogenic than large, buoyant LDL.
P Schwandt, K G Parhofer
exaly +3 more sources
HELP LDL apheresis reduces plasma pentraxin 3 in familial hypercholesterolemia. [PDF]
PLoS ONE, 2014 BackgroundPentraxin 3 (PTX3), a key component of the humoral arm of innate immunity, is secreted by vascular cells in response to injury, possibly aiming at tuning arterial activation associated with vascular damage.
Michela Zanetti +11 more
doaj +2 more sources
The Pathological Role of LDL in Membranous Nephropathy and Diabetic Nephropathy and the Protective Efficacy of LDL Apheresis: A Narrative Review [PDF]
ToxinsDiabetic nephropathy (DN) is the leading cause of end-stage kidney disease worldwide. One-third of patients with DN develop primary glomerulonephritis, and membranous nephropathy (MN) is the most common concurrent glomerulonephritis.
Goh Kodama +5 more
doaj +2 more sources
Frontiers in Immunology, 2022 BackgroundThe SARS-CoV-2 pandemic increased mortality and morbidity among immunocompromised populations. Vaccination is the most important preventive measure, however, its effectiveness among patients depending on maintenance immunoglobulin G (IgG ...
Martina Gaggl +8 more
doaj +1 more source
Asian Journal of Transfusion Science, 2021 Familial hypercholesterolemia (FH) is characterized by an increase in plasma low-density lipoprotein-cholesterol (LDL-C) levels. It presents with tendon/skin xanthomas and premature atherosclerotic cardiovascular disease.
Daljit Kaur +7 more
doaj +1 more source
Cellular cholesterol efflux and cholesterol loading capacity of serum: effects of LDL-apheresis
Journal of Lipid Research, 2012 High LDL-cholesterol (LDL-C) characterizes familial hypercholesterolemia (FH) and familial combined hyperlipidemia (FCH). LDL-apheresis, used in these patients to reduce LDL-C levels, has been shown to also affect HDL levels and composition.
M.P. Adorni +9 more
doaj +1 more source
Journal of Lipid Research, 1990 Low density lipoproteins (LDL) have the potential to serve as cell specific drug carriers. The LDL may be derived in large quantities from LDL-apheresis procedures.
HW Schultis +3 more
doaj +1 more source